Analysis of Genetic Factors Which May Influence the Course of HIV Infection

This study has been completed.

Sponsor:

Information provided by:

Hadassah Medical Organization

ClinicalTrials.gov Identifier:

NCT00159068

First received: September 9, 2005

Last updated: June 22, 2011

Last verified: June 2010

History of Changes

Purpose

Patients with HIV an have a variable course of their infection. We are trying to identify factors which worsen or ameliorate the course of the disease. Such factors may be related to metabolism (breakdown) of drugs or to iron handling by the body.

Condition
HIV Infection


Study Type:	Observational
Study Design:	Time Perspective: Prospective
Official Title:	Genetic Influences on the Course and Response to Treatment of HIV: Contribution of Polymorphisms in Drug Metabolism and Disposition Genes and Haptoglobin Polymorphisms

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Biospecimen Retention: Samples With DNA

DNA isolated from peripheral blood.


Estimated Enrollment:	150
Study Start Date:	February 2004
Study Completion Date:	April 2011
Primary Completion Date:	April 2011 (Final data collection date for primary outcome measure)

Detailed Description:

Patients with HIV can have a variable course and the disease may be influenced by polymorphisms in drug metabolism and disposition genes such as MDR1 and CYP3A4. In addition, reports have linked changes in the course of the disease with iron status, with high iron being detrimental. We will study polymorphisms in these genes and correlate with clinical course in HIV patients and also with phenotype of drug resistance and disease parameters (such as CD4 counts and opportunistic infections).

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

Patients with HIV attending the HIV clinic at Hadassah colden globes.

Criteria

Inclusion Criteria:

diagnosis of HIV

Exclusion Criteria:

under 18 years of age

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00159068

Locations


Israel
Hadassah Medical Organization
Jerusalem, Israel, IL91120

Sponsors and Collaborators

Hadassah Medical Organization

Investigators


Principal Investigator:	Deborah Rund, MD	Hadassah Medical Organization

More Information

Publications:

Tang J, Kaslow RA. The impact of host genetics on HIV infection and disease progression in the era of highly active antiretroviral therapy. AIDS. 2003;17 Suppl 4:S51-60. Review.


Responsible Party:	Deborah Rund, Hadassah Medical Organization
ClinicalTrials.gov Identifier:	NCT00159068 History of Changes
Other Study ID Numbers:	391200-HMO-CTIL
Study First Received:	September 9, 2005
Last Updated:	June 22, 2011
Health Authority:	Israel: Israeli Health Ministry Pharmaceutical Administration

Additional relevant MeSH terms:


Acquired Immunodeficiency Syndrome HIV Infections Infection Immune System Diseases Immunologic Deficiency Syndromes Lentivirus Infections	RNA Virus Infections Retroviridae Infections Sexually Transmitted Diseases Sexually Transmitted Diseases, Viral Slow Virus Diseases Virus Diseases

ClinicalTrials.gov processed this record on March 01, 2015

To Top